Dupuis Elizabeth A, White Hilary F, Newman Daniel, Sobieraj Jerome E, Gokhale Manjusha, Freund Karen M
Women's Health Unit, Section of General Internal Medicine, Evans Department of Medicine, and Women's Health Interdisciplinary Research Center, Boston University School of Medicine, 801 Massachusetts Avenue, Suite 470, Boston, MA 02118, USA.
J Gen Intern Med. 2010 Jun;25(6):575-80. doi: 10.1007/s11606-010-1287-z. Epub 2010 Mar 4.
System level barriers have been associated with inadequate follow-up of abnormal cervical cytology.
The aim of this study was to develop and evaluate an electronic tracking system to improve follow-up of abnormal Pap tests.
We implemented an electronic medical record (EMR)-based Pap test tracking system at two clinical practices at an inner-city academic health center. The system generated a provider-specific monthly report of all abnormal Pap results, and provided a patient-specific Pap tracking table embedded in the EMR for each subject.
We compared abnormal Pap test follow-up rates for the 24 months pre-intervention with rates 12 months following its implementation (post-intervention). The evaluation followed all subjects for 12 months from the date of their abnormal Pap test, looking for diagnostic resolution.
Subjects were young women (mean age = 30.5) of primarily white (42%) and African American (37%) descent, who spoke English (88%). Forty-eight percent were insured through publicly subsidized insurance. Controlling for type of abnormality and practice location, the adjusted mean time to resolution decreased significantly from 108 days (confidence interval, CI 105-112 days) in the pre-intervention period to 86 days (CI 81-91 days).
Our study cannot demonstrate that with follow up, we directly avoided cases of invasive cervical cancer. However, we show that in an at-risk urban population, an automated, EMR-based tracking system reduced the time to resolution, and increased the number of women who achieved diagnostic resolution.
系统层面的障碍与宫颈细胞学异常后续跟进不足有关。
本研究旨在开发并评估一种电子追踪系统,以改善巴氏涂片异常结果的后续跟进情况。
我们在市中心一家学术健康中心的两家临床机构实施了基于电子病历(EMR)的巴氏涂片检测追踪系统。该系统生成了针对每位医护人员的所有异常巴氏涂片结果的月度报告,并为每个受试者在电子病历中嵌入了一份针对患者的巴氏涂片追踪表。
我们将干预前24个月的异常巴氏涂片检测后续跟进率与实施后12个月(干预后)的比率进行了比较。评估从异常巴氏涂片检测之日起对所有受试者进行了12个月的跟踪,以寻找诊断结果。
受试者为年轻女性(平均年龄 = 30.5岁),主要为白人(42%)和非裔美国人(37%)后裔,说英语的占88%。48%的人通过公共补贴保险参保。在控制异常类型和医疗机构地点后,调整后的平均解决时间从干预前期的108天(置信区间,CI 105 - 112天)显著降至86天(CI 81 - 91天)。
我们的研究无法证明通过后续跟进能直接避免浸润性宫颈癌病例。然而,我们表明,在处于风险中的城市人群中,基于电子病历的自动化追踪系统缩短了解决时间,并增加了获得诊断结果的女性人数。